Free Trial

HLS Therapeutics (HLS) Stock Forecast & Price Target

HLS Therapeutics logo
C$3.52 -0.04 (-1.12%)
(As of 12/3/2024 ET)

HLS Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
1

Based on 1 Wall Street analysts who have issued ratings for HLS Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for HLS.

Consensus Price Target

C$4.13
17.19% Upside
According to the 1 analysts' twelve-month price targets for HLS Therapeutics, the average price target is C$4.13. The highest price target for HLS is C$5.00, while the lowest price target for HLS is C$3.25. The average price target represents a forecasted upside of 17.19% from the current price of C$3.52.
Get the Latest News and Ratings for HLS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HLS Therapeutics and its competitors.

Sign Up

HLS Analyst Ratings Over Time

TypeCurrent Forecast
12/5/23 to 12/4/24
1 Month Ago
11/5/23 to 11/4/24
3 Months Ago
9/6/23 to 9/5/24
1 Year Ago
12/5/22 to 12/5/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
Hold
0 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetC$4.13C$3.63C$3.63C$10.50
Forecasted Upside17.19% Upside9.85% Upside12.93% Upside191.67% Upside
Consensus Rating
Buy
Hold
Hold
Hold

HLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HLS Therapeutics Stock vs. The Competition

TypeHLS TherapeuticsMedical Companies
Consensus Rating Score
3.00
2.81
Consensus RatingBuyModerate Buy
News Sentiment Rating
Neutral News

See Recent HLS News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/22/2024Raymond James
4 of 5 stars
 Boost TargetC$4.00 ➝ C$5.00+42.86%
8/13/2024Stifel Nicolaus
4 of 5 stars
 Lower TargetC$3.75 ➝ C$3.25+4.84%
2/6/2024Clarus Securities
5 of 5 stars
G. Ulybyshev
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
11/9/2023Stifel Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Keywood
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/17/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$21.75 ➝ C$17.50+175,000,000.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:01 AM ET.


HLS Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for HLS Therapeutics is C$4.13, with a high forecast of C$5.00 and a low forecast of C$3.25.

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLS shares.

According to analysts, HLS Therapeutics's stock has a predicted upside of 17.19% based on their 12-month stock forecasts.

HLS Therapeutics has been rated by research analysts at Raymond James in the past 90 days.

Analysts like HLS Therapeutics more than other "medical" companies. The consensus rating for HLS Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLS compares to other companies.


This page (TSE:HLS) was last updated on 12/4/2024 by MarketBeat.com Staff
From Our Partners